Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Metabolix Secures UCLA Engineering ARPA-E Grant for Improving the Productivity of Making Biofuels in Plants



  Metabolix Secures UCLA Engineering ARPA-E Grant for Improving the
  Productivity of Making Biofuels in Plants

     Third Grant in 2012 Focusing on Company’s Leading-Edge Crop Research

Business Wire

CAMBRIDGE, Mass. -- December 06, 2012

Metabolix, Inc. (NASDAQ: MBLX), an innovation-driven bioscience company
focused on delivering sustainable solutions for plastics, chemicals and
energy, today announced that it has received a subaward under the Advanced
Research Projects Agency – Energy (ARPA-E) to work with the UCLA Henry Samueli
School of Engineering and Applied Science to redesign carbon fixation pathways
to increase the efficiency of capturing energy from sunlight. This is the
third grant awarded to Metabolix in 2012 for leading-edge crop research
targeting multi-gene expression and transformation of plants, and builds upon
its years of experience in transforming plants for bio-product production.
Funding from these three grants will total nearly $1 million and will run
through 2014.

Under the UCLA Engineering ARPA-E grant, Metabolix researchers will work
closely with Professor James Liao, the Ralph M. Parsons Foundation professor
and chair in the department of chemical and biomolecular engineering and a
recent Presidential Green Chemistry Challenge Award recipient, to engineer
alternate biochemical pathways for carbon fixation into the crop plant,
camelina. Metabolix’s multi-gene expression technology and its significant
prior work in camelina will help increase the number of new traits expressed
in each plant, which is expected to produce new pathways to a greater variety
of liquid fuels from camelina and other plants. Specifically, the ARPA-E grant
focuses on carbon fixation, which is the key process that plants use to
convert carbon dioxide (CO[2]) from the atmosphere into higher energy
molecules (such as sugars) using energy from the sun. Metabolix will work with
UCLA Engineering to investigate an alternative biochemical pathway that
theoretically could allow a plant to capture twice as much CO[2] using the
same amount of light, with the end goal of improving the productivity of both
food and fuel crops.

“Metabolix brings a unique set of capabilities and experience as well as a
proven track record of success in plant science to our ARPA-E project,” said
Dr. Liao. “With its proven capability to engineer a variety of crop plants for
the production of industrial products, Metabolix will be a valuable partner in
our work to increase carbon fixation in plants and enable the production of a
greater variety of liquid fuels in camelina and other plants. We look forward
to working with Metabolix in our quest to generate more cost-effective
biofuels.”

“We are delighted that another of our project teams has chosen to work with
Metabolix to move PETRO's high-performance, dedicated energy crops closer to
realization,” says ARPA-E Program Director Dr. Jonathan Burbaum. “If
successful, such crops promise to provide a viable, domestic and renewable
alternative to imported petroleum.”

The UCLA Engineering ARPA-E grant is the third crops science grant awarded to
Metabolix in 2012. In January, the Company initiated work on an ARPA-E-funded
project to work with the University of Massachusetts (UMass) Amherst to help
increase the natural ability of camelina to produce oils and add the
production of energy-dense terpene molecules that can be easily converted into
liquid fuels. In April, Metabolix Oilseeds, a wholly owned subsidiary of
Metabolix, was awarded a grant for the development of capacity building for
commercial-scale polyhydroxybutyrate (PHB)-producing camelina.

“Driving a growing interest in our crops science program is the interest from
brand owners, consumers and government organizations for developing renewable,
non-petroleum-based liquid fuels,” said Dr. Oliver Peoples, chief scientific
officer and vice president, research at Metabolix. “Metabolix is a pioneer in
plant science and we have a deep history working with leading institutions to
successfully further the development of technologies to enhance the
productivity of crops. We look forward to applying our strong capabilities in
crop science to the work with UCLA Engineering to improve the carbon fixation
pathways of camelina and produce new routes to biofuels.”

About Metabolix

Metabolix, Inc. is an innovation-driven bioscience company delivering
sustainable solutions to the plastics, chemicals and energy industries.
Metabolix is developing and commercializing Mirel^TM and Mvera,^TM a family of
high-performance bioplastics which are biobased and biodegradable alternatives
to many petroleum-based plastics. Metabolix’s biobased chemicals platform
utilizes its novel “FAST” recovery process to enable the production of
cost-effective, “drop-in” replacements for petroleum-based industrial
chemicals. Metabolix is also developing a platform for co-producing plastics,
chemicals and energy from crops. Metabolix has established an industry-leading
intellectual property portfolio that, together with its knowledge of advanced
industrial practice, provides a foundation for industry collaborations.

For more information, please visit www.metabolix.com. (MBLX-G)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant
to the safe harbor provisions of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
The forward-looking statements in this release do not constitute guarantees of
future performance. Investors are cautioned that statements in this press
release which are not strictly historical statements, including, without
limitation, statements regarding the expected results of Metabolix research
programs, constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated and are detailed in
Metabolix's filings with the Securities and Exchange Commission. Metabolix
assumes no obligation to update any forward-looking information contained in
this press release or with respect to the announcements described herein.

Contact:

Media and General Inquiries:
Metabolix, Inc.
Lynne H. Brum, 617-682-4693
LBrum@metabolix.com
or
Schwartz MSL Boston
Keith Giannini or Kirsten Swenson, 781-684-0770
metabolix@schwartzmsl.com
or
Investors:
ICR
James Palczynski, 203-682-8229
james.palczynski@icrinc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement